The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is characterized by a range of pathophysiologic changes that contribute to a highly variable clinical presentation as well as heterogeneity among patients. In addition to airflow limitation, the integral evaluation of COPD needs to consider at least several aspects, such as symptoms, exacerbations and comorbidities [@pone.0105220-Global1], [@pone.0105220-TaskForcefor1].

Comorbidities occur frequently in COPD patients but show great variability in reported prevalence [@pone.0105220-Chatila1]. COPD is often associated with significant nutritional abnormalities in particular. Extra-pulmonary manifestations such as low body weight, low body mass index (BMI) and depletion of fat-free mass have been extensively reported [@pone.0105220-Schols1], [@pone.0105220-Bernard1], and they are recognized as independent prognostic factors in COPD patients [@pone.0105220-Landbo1], [@pone.0105220-Celli1], often considered in the more advanced, late COPD stages and an indication of an emphysematous phenotype.

Although low BMI and muscle wasting have traditionally been the focus of nutritional assessment in COPD [@pone.0105220-Celli1], recent data indicate that obesity is becoming frequent in this disease [@pone.0105220-Guerra1] and some evidence suggests that obesity might contribute to respiratory symptoms and exercise limitation, regardless of airflow obstruction [@pone.0105220-GarcaRodrguez1]. However, the current evidence of a possible association between obesity and poorer COPD disease state is still limited.

Most studies concerning the prevalence of nutritional alterations in COPD have been performed in selected populations [@pone.0105220-Schols2]--[@pone.0105220-Chailleux1] and the impact of BMI on health status and prognosis seems to differ with COPD stage. In fact, in some studies, obese patients with more severe COPD appear to have better outcomes ("obesity paradox") [@pone.0105220-Landbo1]. Little information is available regarding the BMI distribution in COPD patients from population-based studies [@pone.0105220-MontesdeOca1], [@pone.0105220-Vozoris1], which is necessary to more accurately represent the total spectrum of patients with the disease, and to provide more unbiased inferences.

We have analyzed the EPI-SCAN study [@pone.0105220-Ancochea1], [@pone.0105220-Miravitlles1] aiming to characterize the BMI distribution in a population-based sample of COPD patients and to evaluate the impact of obesity on health status, exercise tolerance, daily physical activity, systemic inflammation and comorbidity.

Materials and Methods {#s2}
=====================

The study was approved by the corresponding ethics committees (Hospital Clinic, Barcelona, Spain). All participants gave written informed consent to participate in the study.

Study population {#s2a}
----------------

We used data from the EPI-SCAN study, a multicenter, cross-sectional, population-based study conducted at 11 locations throughout Spain. Out of a total of 4,274 subjects who had been randomly contacted by telephone at the 11 sites, 3,885 agreed to participate in the study and a final group of 3,797 (88.8%) were available for analysis (complete minimum data set on gender, age and lung function). The 389 (9.1%) who refused to take part in the survey were slightly older and there were more women as well as never and former smokers. Complete details of the methodology, detailed descriptions of participation rates, and sample characteristics of the EPI-SCAN study have been published elsewhere [@pone.0105220-Miravitlles1]. For the present study, our source population included 3,797 non-institutionalized participants aged 40--80 who completed acceptable spirometry [@pone.0105220-Miller1].

Procedures {#s2b}
----------

Body weight was assessed with a beam scale (measured to the nearest 0.1 kg) with subjects standing barefoot and in light clothing. Height was measured by a clinical stadiometer in bare or stocking feet. BMI, defined as weight (kg) divided by the square of height (meters), was calculated. Patients were categorized by World Health Organization (WHO) criteria as [@pone.0105220-World1]: underweight (BMI\<18.5 kg/m^2^), normal weight (BMI 18.5--24.9 kg/m^2^), overweight (BMI 25.0--29.9 kg/m^2^) and obese (BMI≥30.0 kg/m^2^).

Patient-reported data for smoking history, educational level, domestic and occupational exposures, respiratory history and symptoms, previous medication and use of health services during the preceding year were collected. Any respiratory exacerbation that required a change in regular medication was considered mild, while a respiratory exacerbation treated with a course of oral corticosteroids or antibiotics was considered moderate. Self-reported comorbidity was documented using the Charlson index. The presence of heart failure, ischemic heart disease, peripheral vascular disease or cerebrovascular disease was coded as cardiovascular disease.

Baseline dyspnea was assessed by the Modified Medical Research Council (mMRC) scale, and subjects completed the ECSC respiratory symptoms questionnaire, the Spanish versions of the London Chest Activity of Daily Living (LCADL) scale, the EQ-5D questionnaire and the St. George\'s Respiratory Questionnaire.

Blood samples were collected using standardized procedures and stored at −80°C for biomarker analysis, as previously described [@pone.0105220-GarcaRo1]. The biomarkers analyzed were: C-reactive protein (CRP), TNF-α, interleukin (IL)-6, IL-8, fibrinogen and nitrites/nitrates (NOx).

Pre- and post-bronchodilator spirometries were performed at each center using the same equipment and in accordance with current recommendations, as described in previous publications [@pone.0105220-Ancochea1], [@pone.0105220-Miravitlles1]. A bronchodilator test was considered positive when there was an increase in FEV~1~ or FVC≥12% and ≥200 ml. Six-minute walk tests were performed following current guidelines [@pone.0105220-ATS1]. To control for a learning effect, 2 walks were performed with a 30-minute rest in between. Walk-work was defined as 6-min walk distance × weight (in kg).

COPD was defined by a post-bronchodilator FEV~1~/FVC ratio \<0.70 [@pone.0105220-Global1] and, in accordance with the new GOLD 2011 stage grades [@pone.0105220-Global1], COPD patients were classified in groups A (low risk, fewer symptoms), B (low risk, more symptoms), C (high risk, fewer symptoms) or D (high risk, more symptoms), using predicted FEV~1~, mMRC and exacerbation history. COPD severity was determined by the BODE [@pone.0105220-Celli1] and ADO [@pone.0105220-Puham1] indices. Subjects with a post-bronchodilator FEV~1~/FVC ratio ≥0.70 were considered not to have COPD.

Statistical analysis {#s2c}
--------------------

Values are expressed as mean ± standard deviation or count and percentage. Differences between study groups were analyzed using the Chi-squared test or ANOVA with post-hoc analysis by the Bonferroni test. In this analysis, a logarithmic transformation was used in those variables not normally distributed, to reduce their skewness. The effect of possible confounding factors was assessed using a generalized linear model analysis adjusted for age, gender, pack-years and post-bronchodilator FEV~1~ (% pred.).

In order to examine associations between variables, odds ratios were calculated by logistic regression. We developed multiple logistic regression models with adjustment for age, gender, pack-years and post-bronchodilator FEV~1~ (% pred.).

Analyses were performed with SPSS 14.0 for Windows (SPSS, Inc., Chicago, IL). A two-sided p value \<0.05 was considered statistically significant.

Results {#s3}
=======

From the population-based sample of 3,797 subjects, 385 (10.1%) had post-bronchodilator FEV~1~/FVC\<0.7. In comparison with the non-COPD subjects, COPD patients showed a higher prevalence of obesity (29.4%, 95%CI 24.8--33.9% vs. 24.3, 95%CI 22.9--25.8) and of being overweight (44.7%, 95%CI 39.7--49.6% vs. 43.0%, 95% CI 41.3--44.6%) (p = 0.020). In the global sample, being underweight was very uncommon, both in COPD patients (0.8%, 95% CI 0.0--1.7%) as well as in non-COPD subjects (0.5%, 95%CI 0.2--0.7%). [Figure 1](#pone-0105220-g001){ref-type="fig"} shows the BMI distribution in the COPD and non-COPD subjects according to age strata.

![Distribution of BMI classifications according to age group in COPD and non-COPD subjects.](pone.0105220.g001){#pone-0105220-g001}

[Table 1](#pone-0105220-t001){ref-type="table"} demonstrates the main characteristics of the normal-weight, overweight and obese COPD groups. In comparison with the normal-weight COPD patients, overweight and obese patients were older and had greater smoking intensity, whereas no differences in gender, occupational exposure or education level were found. FVC and FEV~1~ were slightly lower in obese COPD patients than in the other groups, without significant differences in inspiratory capacity or reversibility. Moreover, obese COPD patients walked less distance during six minutes, with a higher walk work than COPD patients with normal weight or overweight. Similarly, comorbidities were more frequent in obese COPD patients than in the other two groups, often associated with the presence of cardiovascular disease or diabetes mellitus. GOLD 2011 grade distribution was also different among the COPD patient groups. Obese COPD patients also showed higher multidimensional severity indices than the other groups and they more frequently used respiratory medication, specifically beta-agonists, methylxanthines and inhaled corticosteroids.

10.1371/journal.pone.0105220.t001

###### General characteristics, functional status and severity of the COPD groups.

![](pone.0105220.t001){#pone-0105220-t001-1}

                                                                Normal weight     Overweight         Obesity          Total         p
  ------------------------------------------------------------ --------------- ---------------- ----------------- ------------- ---------
  Patients, n                                                        97              172               113             382      
  Males, %                                                          63.9%           75.6%             68.1%           70.4%       0.108
  Age, yr.                                                          61±10          64±11^‡^          66±9^†^          64±10       0.001
  BMI, Kg/m^2^                                                    22.9±1.7         27.4±1.5         33.7±3.7        28.1±4.7     \<0.001
  Smoking status                                                   \<0.001                                                      
  Current smoker, %                                                 50.5             33.7             19.5            33.8      
  Former smoker, %                                                  33.0             39.0             48.7            40.3      
  Never smoker, %                                                   16.5             27.3             31.9            25.9      
  Smoking exposure, pack-years                                    34.1±21.6      43.3±29.1^‡^     46.1±24.9^‡^      41.4±26.3     0.009
  Self-reported exposure to vapors, gases, dusts or fumes, %        38.1             34.9             43.4            38.2        0.354
  Occupational exposure                                                                                                         
  Biological dusts, %                                               25.8             19.8             30.1            24.3        0.130
  Mineral dusts, %                                                  28.9             24.4             25.7            25.9        0.725
  Gases or fumes, %                                                 25.8             15.7             24.8            20.9        0.073
  Retired or disabled, %                                            67.0             72.7             87.5            75.6        0.001
  Education level                                                   0.096                                                       
  Less than primary school, %                                       14.6             14.0             20.4            16.0      
  Primary school, %                                                 34.4             37.2             47.8            39.6      
  Secondary school, %                                               25.0             27.3             21.2            24.9      
  University degree, %                                              24.0             19.8             10.6            18.1      
  Pulmonary function                                                                                                            
  Post-bronchodilator FVC, % pred.                                 110±20           107±21         100±21^†§^        106±21       0.002
  Post-bronchodilator FEV~1~, % pred.                               85±20           85±19             79±19           83±20       0.037
  Post-bronchodilator FEV~1~/FVC, %                                 62±9             62±7             62±7            62±8        0.976
  Post-bronchodilator IC, % pred.                                  103±28           109±26           106±27          106±27       0.239
  Reversibility (positive bronchodilator  test) (%)                 20.2             31.0             25.9            26.8        0.161
  6-min walk test                                                                                                               
  Distance, m                                                      468±122         460±114         405±131^†¶^       447±123      0.001
  Walk work (m. Kg)                                              30723±8645     36152±10280^†^   39329±12504^†¶^   35251±10912   \<0.001
  Δ SpO~2~, %                                                    −1.13±2.09       −0.69±2.02       −1.01±3.35      −0.90±2.49     0.377
  Δ Borg                                                          0.87±1.22       0.78±1.12         0.98±1.24       0.86±1.17     0.451
  Δ Borg/distance walked, %/100 m                                  0.23±43        0.19±0.32         0.36±0.93       0.25±0.59     0.085
  Comorbidity                                                                                                                   
  Cardiovascular diseases, %                                         9.3             15.7             31.9            18.8       \<0.001
  Diabetes mellitus, %                                               7.2             9.3              19.5            11.8        0.009
  Peptic ulcer disease, %                                           10.3             7.6               5.3             7.6        0.395
  Neoplasm, %                                                        7.2             6.4               5.3             6.3        0.848
  Charlson index                                                  0.90±1.01       0.84±0.96       1.29±1.15^‡¶^     0.99±1.04     0.001
  GOLD risk stage                                                  \<0.001                                                      
  A, %                                                              66.0             59.3             33.6            53.4      
  B, %                                                              20.6             32.0             47.8            33.8      
  C, %                                                               2.1             1.2               4.4             2.4      
  D, %                                                              11.3             7.6              14.2            10.5      
  BODE index                                                      1.10±1.55       0.86±1.23       1.61±1.78^§^      1.13±1.53     0.001
  ADO index                                                       2.28±1.69       2.58±1.64       3.31±1.52^†¶^     2.72±1.66    \<0.001
  COPD previous diagnosis, %                                        29.9             20.9             33.6            27.0        0.046
  Current treatment                                                                                                             
  Short-acting beta-agonists, %                                     13.4             11.6             27.4            16.9        0.001
  Long-acting beta-agonists, %                                      17.5             17.4             30.1            21.2        0.023
  Anticholinergics, %                                               14.4             11.0             20.4            14.7        0.094
  Methylxanthines, %                                                 2.1              0                4.4             1.8        0.024
  Inhaled corticosteroids, %                                        18.6             19.8             31.9            23.0        0.029

Values are mean ±SD or frequency. Abbreviations: BMI = body mass index; FVC = forced vital capacity; FEV~1~ = forced expiratory volume in 1 second; IC = inspiratory capacity; SpO~2~ = oxyhemoglobin saturation.

Comparisons between groups by ANOVA with Bonferroni post-hoc comparisons: ^†^p\<0.01 vs. normal weight group; ^‡^p\<0.05 vs. normal weight group; ^¶^p\<0.01 vs. overweight group; ^§^p\<0.05 vs. overweight group.

The comparison of symptoms, exacerbation history, health status and systemic inflammatory biomarkers of the three study groups are presented in [table 2](#pone-0105220-t002){ref-type="table"}. Dyspnea and wheezing were more frequent in obese COPD patients, while chronic bronchitis and phlegm resulted more frequent in COPD patients with normal weight. Significant differences in health-related quality of life, daily physical activity and inflammatory biomarker levels were noted among the three groups. In the adjusted comparison, both dyspnea and health status were worse in obese COPD patients than in overweight COPD patients ([Table 3](#pone-0105220-t003){ref-type="table"}). Reduced exercise tolerance and higher walk work were found in obese patients, although daily physical activity did not reach significant differences between the study groups. Finally, systemic pro-inflammatory state was increased in obese or overweight COPD patients compared with COPD patients with normal weight, showing higher plasmatic CRP levels. Mild and moderate exacerbations and hospitalizations were not significantly different among the three groups.

10.1371/journal.pone.0105220.t002

###### Comparison of symptoms, previous exacerbations, health status and systemic biomarker levels between the study groups.

![](pone.0105220.t002){#pone-0105220-t002-2}

                                                                            Normal weight    Overweight       Obesity        Total        p
  ------------------------------------------------------------------------ --------------- -------------- --------------- ----------- ---------
  Symptoms                                                                                                                            
  Chronic cough, %                                                              39.6            32.0           25.0          31.8       0.079
  Chronic bronchitis, %                                                         29.9            18.6           12.6          19.7       0.007
  Chronic phlegm, %                                                             39.2            31.4           21.4          30.4       0.020
  Dyspnea, %                                                                    20.6            23.4           44.2          28.9      \<0.001
  mMRC                                                                        1.49±0.86      1.52±0.75     1.92±0.91^†¶^   1.63±0.84   \<0.001
  Wheezing, %                                                                   64.9            58.1           72.6          64.1       0.045
  Mild respiratory exacerbations in the previous year, n per patient          0.10±0.47      0.30±1.77       0.31±0.80     0.25±1.29    0.411
  Moderate respiratory exacerbations in the previous year, n per patient      0.45±1.07      0.33±1.05       0.48±0.81     0.40±0.99    0.380
  Hospitalizations in the previous year, n per patient                        0.02±0.20      0.06±0.41       0.06±0.41     0.05±0.37    0.613
  Health-related quality of life                                                                                                      
  SGRQ symptoms                                                               29.1±22.8      23.8±21.1       29.2±22.5     26.8±22.1    0.088
  SGRQ activity                                                               26.1±27.0      25.6±23.1     38.7±24.9^†¶^   29.5±25.3   \<0.001
  SGRQ impact                                                                 14.6±18.7      12.0±15.1       16.6±17.2     14.0±16.8    0.109
  Total SGRQ                                                                  20.7±20.2      18.4±16.5     25.7±18.1^¶^    21.1±18.2    0.008
  EQ-5D VAS score                                                             71.6±16.7      73.1±15.6     66.7±18.6^§^    70.8±17.0    0.013
  EQ-5D utility score                                                         0.83±0.24      0.90±0.19       0.83±0.21     0.86±0.21    0.022
  LCADL total                                                                 17.1±8.1        15.6±4.1      17.7±7.2^§^    16.6±6.4     0.030
  Systemic biomarkers                                                                                                                 
  CRP, log (mg/l)                                                             0.37±0.31      0.51±0.45     0.60±0.40^†^    0.50±0.41    0.003
  TNF-alpha, log (pg/ml)                                                      0.97±0.27     1.06±0.28^‡^     1.06±0.52     1.04±0.27    0.036
  IL-6, log (pg/ml)                                                           0.48±0.34      0.46±0.34       0.54±0.35     0.49±0.34    0.216
  IL-8, log (pg/ml)                                                           0.51±0.64      0.43±0.60       0.41±0.55     0.44±0.60    0.482
  Fibrinogen, g/l                                                             3.24±0.91      3.57±1.13     3.77±1.08^†^    3.54±1.08    0.005
  NOx, log (nmol/l)                                                           1.43±0.18      1.42±0.25       1.40±0.22     1.42±0.23    0.625

Values are mean ± SD or frequency. Abbreviations: BMI = body mass index; mMRC = modified Medical Research Council dyspnea scale; SGRQ = St. George\'s Respiratory Questionnaire; EQ-5D = EuroQol 5 Dimensions questionnaire; VAS = Visual analogue scale; LCADL = London Chest Activities of Daily Living; CRP = C-reactive protein; TNF = tumor necrosis factor; IL = interleukin; NOx = nitrites/nitrates.

Comparisons between groups by ANOVA with Bonferroni post-hoc comparisons: ^†^p\<0.01 vs. normal weight group; ^‡^p\<0.05 vs. normal weight group; ^¶^p\<0.01 vs. overweight group; ^§^p\<0.05 vs. overweight group.

10.1371/journal.pone.0105220.t003

###### Adjusted comparisons of health status, exercise tolerance and systemic inflammatory biomarkers between the study groups.

![](pone.0105220.t003){#pone-0105220-t003-3}

                                    Normal weight    Overweight       Obesity         p
  -------------------------------- --------------- -------------- --------------- ---------
  mMRC                                1.58±0.09      1.48±0.07     1.81±0.09^§^     0.017
  Health-related quality of life                                                  
  SGRQ symptoms                       29.3±2.6        24.5±2.0       26.5±2.6       0.332
  SGRQ activity                       28.4±2.8        24.9±2.2      35.9±2.8^¶^     0.008
  SGRQ impact                         15.2±1.9        11.6±1.5       14.6±2.0       0.250
  Total SGRQ                          21.8±2.1        18.0±1.6       23.3±2.1       0.098
  EQ-5D VAS score                     71.3±1.9        74.0±1.5      67.9±2.0^§^     0.048
  EQ-5D utility score                 0.82±0.02      0.91±0.02     0.86±0.03^‡^     0.017
  LCADL total                         17.3±0.7        15.4±0.6       16.8±0.7       0.097
  Distance 6-min walking test, m       450±14          471±11        422±15^§^      0.043
  Walk work, m. Kg                   28144±1246     36815±981^†^   40232±1302^†^   \<0.001
  Systemic biomarkers                                                             
  CRP, log (mg/l)                     0.40±0.05     0.54±0.04^‡^   0.57±0.05^‡^     0.033
  TNF-alpha, log (pg/ml)              0.97±0.03      1.05±0.03       1.03±0.04      0.218
  IL-6, log (pg/ml)                   0.48±0.04      0.48±0.03       0.57±0.04      0.231
  IL-8, log (pg/ml)                   0.53±0.07      0.42±0.06       0.42±0.07      0.416
  Fibrinogen, g/l                      3.4±0.1        3.5±0.1         3.6±0.1       0.431
  Albumin, g/l                        45.2±0.3        45.4±0.3       46.0±0.4       0.188
  NOx, log (nmol/l)                   1.44±0.03      1.44±0.02       1.41±0.03      0.589

Values are mean ± SEM. Comparisons adjusted by gender, age, pack-year and FEV~1~ (% pred). Abbreviations: mMRC = modified Medical Research Council dyspnea scale; SGRQ = St. George\'s Respiratory Questionnaire; EQ-5D = EuroQol 5 Dimensions questionnaire; VAS = Visual analogue scale; LCADL = London Chest Activities of Daily Living; CRP = C-reactive protein; TNF = tumor necrosis factor; IL = interleukin; NOx = nitrites/nitrates.

Post-hoc comparisons between groups by Bonferroni test: ^†^p\<0.001 vs. normal weight group; ^‡^p\<0.05 vs. normal weight group; ^¶^p\<0.01 vs. overweight group; ^§^p\<0.05 vs. overweight group.

After multivariate adjustment, differences in multidimensional COPD assessment and in the Charlson index remained among the three study groups ([Figure 2](#pone-0105220-g002){ref-type="fig"}). Consistently, BODE and ADO indices were higher in obese COPD patients than in overweight COPD subjects. In turn, comorbidities were more frequent in the obese patients than in the other two COPD groups.

![Adjusted comparisons of multidimensional indices and comorbidity between the three groups of COPD patients.\
Mean values are adjusted for gender, age, packs-year and FEV~1~ (% pred.). Error bars represent SEM.](pone.0105220.g002){#pone-0105220-g002}

Adjusted odds ratios for comorbidity and respiratory symptoms by COPD group are shown in [Figure 3](#pone-0105220-g003){ref-type="fig"}. In comparison with normal-weight COPD patients, the obese patients presented a greater prevalence of cardiovascular diseases (adjusted odds ratio \[OR\] 4.796, 95%CI 1.806--12.736, p = 0.002) and a different symptomatic profile. The obese COPD patients had lower risk for presenting chronic cough (adjusted OR 0.364, 95% CI 0.178--0.743, p = 0.005), chronic bronchitis (adjusted OR 0.321, 95%CI 0.142--0.724, p = 0.006) or chronic phlegm (adjusted OR 0.398, 95%CI 0.197--0.804, p = 0.010) than COPD patients with normal weight, whereas they had more dyspnea (adjusted OR 2.679, 95%CI 1.307--5.489, p = 0.007).

![Adjusted risk of comorbidity and respiratory symptoms in overweight and obese COPD patients compared with normal-weight COPD patients.\
Values are adjusted for gender, age, packs-year and FEV~1~ (% pred.).](pone.0105220.g003){#pone-0105220-g003}

Discussion {#s4}
==========

Our study shows that being underweight is uncommon in a population-based series of COPD patients, while obesity affects more than 29% of patients and is more frequent than in subjects without airflow limitation. Also, the presence of obesity determines the clinical behavior of COPD, with more prevalence and severity of dyspnea and less frequency of cough and expectoration, worse quality of life, reduced exercise tolerance, more systemic inflammation and major cardiovascular comorbidity.

Although a previous population study [@pone.0105220-MontesdeOca1] reported a slightly higher incidence (6.7%) of underweight patients, it used a different cut-point than that established by the WHO (BMI\<20 Kg/m^2^). Our results concur with a series from the US Department of Veterans Affairs Puget Sound Health Care System, which reported only 1.1% of patients with a BMI\<18.5 Kg/m^2^ [@pone.0105220-Cecere1]. In another study, a prevalence of self-reported underweight lower than 4% has been reported [@pone.0105220-Vozoris1]. With regards to obesity, the prevalence observed in our COPD patients (29%) concurs with a large Canadian pulmonary function laboratory database (29%) [@pone.0105220-ODonnel1], the PLATINO study (23%) [@pone.0105220-MontesdeOca1] and Canadian National Health Survey (24.6%) studies [@pone.0105220-Vozoris1]. Moreover, our data confirm that obesity is more prevalent in patients with COPD than in the general population, which probably depends on the severity of chronic airflow limitation. In fact, there is evidence for higher prevalence of obesity in patients with early stage COPD [@pone.0105220-GarcaRodrguez1] and it has been reported that obesity is more prevalent in COPD patients with mild obstruction than in severe patients [@pone.0105220-ekerevac1]. It is likely that the correlation with severity justifies both the high prevalence of obesity as well as the very low incidence of underweight patients in population studies in which the patient group is mainly comprised of subjects with mild-moderate disease.

The three COPD groups (normal weight, overweight and obese) compared in our study were not homogenous in age or smoking history. Obese patients were older, probably reflecting the physiological weight increase that happens with age and sedentarism associated with exercise- and effort-induced dyspnea [@pone.0105220-Rennard1]. Moreover, and in agreement with Cecere et al. [@pone.0105220-Cecere1], obese patient groups had a lower frequency of current smokers, although the cumulative smoking exposure was higher, probably due to an age effect.

As for lung function, the FVC and FEV~1~ of our obese patients were lower than those of normal-weight patients. These findings, which have also been identified in other studies [@pone.0105220-Cecere1], [@pone.0105220-VandenBemt1], coincide with common physiological abnormalities classically associated with simple obesity, such as decreased chest wall and lung compliance, small airway dysfunction and expiratory flow limitation [@pone.0105220-Franssen1]. Contrarily, the lack of differences in inspiratory capacity among our patient groups contradicts with previous information from O\'Donnell et al. [@pone.0105220-ODonnel1], who reported a directly proportional relationship between BMI and resting IC, suggesting that obesity might reduce lung hyperinflation. This discordance could be attributed to the differing severity and age of the patients included in the two studies, and particularly to the fact that in the O\'Donnell study the obese patients were younger than the patients with normal weight, while in our study the opposite was true.

Possibly one of the most prominent findings of our study lies in the impact of obesity on the symptoms profile of COPD patients, where patients with obesity had more dyspnea and less cough and expectoration than patients with normal weight. An analysis of the PLATINO study [@pone.0105220-MontesdeOca1] also reported a higher frequency of dyspnea and wheezing in obese patients, although there were no variations in cough or phlegm. In addition to being more frequent, dyspnea is also more intense in obese patients compared with normal-weight patients, even after adjusting for airflow limitation and other variables. Compared with a small clinical series of COPD patients [@pone.0105220-Ora1] that identified lower baseline dyspnea in obese patients, which was attributed to lower resting hyperinflation, other more extensive clinical series confirm that obese patients with COPD more frequently experience moderate or severe dyspnea than normal-weight patients [@pone.0105220-Cecere1], [@pone.0105220-VandenBemt1]. A greater perception of the dyspnea associated with obesity may contribute to this finding [@pone.0105220-Salome1]. Moreover, obesity might differ between various clinical phenotypes of COPD, as suggested in the Tucson prospective cohort study [@pone.0105220-Guerra1].

The crude comparison between the patient groups shows that obese COPD patients presented a greater use of respiratory medication and a poorer health-related quality of life. In the adjusted analysis, however, only the EuroQoL showed significant differences between groups, while the SGRQ did not reach statistical significance, possibly reflecting the contribution of other determinants (that are not exclusively respiratory in nature) to the poorer quality of life of obese patients.

An aspect that is particularly important is the potential effect of obesity on the perception of symptoms of patients with asthma-COPD overlap syndrome. Taking into account the fact that obesity notably contributes to the breathlessness of asthma patients [@pone.0105220-Deesomchok1], [@pone.0105220-Shim1] and that some 17% of patients with COPD in our study were categorized as asthma-COPD phenotype [@pone.0105220-Miravitlles2], one could speculate that the clinical impact of obesity was provided exclusively by this patient subgroup. To assess this possibility, Tables S1-S4 in [File S1](#pone.0105220.s001){ref-type="supplementary-material"} present the comparisons between groups while excluding patients with asthma-COPD overlap syndrome, which demonstrates that the effects of obesity on clinical manifestations, quality of life, exercise tolerance and systemic inflammation persist in the remaining COPD patients.

There is a certain discrepancy around the effect of obesity on exercise tolerance in COPD. While reduced tolerance to exercise has been reported [@pone.0105220-ODonnel1], other authors do not identify such effect [@pone.0105220-Ora1], [@pone.0105220-Ischaki1]. Our results confirm that adjusted exercise tolerance is lower in obese patients who reach a shorter distance walked during the 6-minute walk test. Although the mechanisms of exercise intolerance in obese patients with COPD may be complex due to disease heterogeneity and the existence of serious comorbidities, the neuromechanical uncoupling of the respiratory system seems to play some type of role. Compared to normal-weight COPD patients, obese patients have a higher metabolic demand at any given power output as a result of the high oxygen cost of lifting heavy limbs [@pone.0105220-ODonnel1]. Moreover, obese patients with COPD have increased ventilatory demand and more frequently abnormal ventilatory mechanics. In fact, ventilatory requirements are higher in obese COPD patients compared with those of normal weight as a result of combined increased metabolic loading, high fixed physiological dead space and possibly earlier metabolic acidosis [@pone.0105220-Ora1]. Given the increase in ventilatory demand and the mechanical limitation of ventilation, the muscular effort required to sustain ventilation during exercise is also higher [@pone.0105220-ODonnel1]. The net effect of these abnormalities is the increased work and oxygen cost of breathing at any given power output compared with normal-weight individuals, which would be expected to contribute to exercise limitation. This hypothesis coincides with our results that obese patients develop greater walk-work, defined as 6 min walk distance × weight (in kg), and the results of others who demonstrated that obese COPD patients had higher peak symptom-limited oxygen uptake than non-obese patients [@pone.0105220-Ora1], [@pone.0105220-Laviolette1].

In the general population, obesity is a strong risk factor for the development and progression of hypertension, dyslipidemia, metabolic syndrome, and type-2 diabetes mellitus [@pone.0105220-Lavie1]. Our results confirm this effect in COPD patients and that the presence of obesity almost multiplies five-fold the risk for presenting cardiovascular comorbidity. In this sense, it has been reported that the application of cluster analysis to segregate COPD patients into different phenotypes has been able to identify a group characterized by obesity and cardiovascular disease [@pone.0105220-GarciaAymerich1]. This association is particularly relevant because several studies have shown that cardiovascular diseases, along with lung cancer, are among the main causes of death in COPD patients not selected by severity criteria [@pone.0105220-Mannino1], [@pone.0105220-Nicholas1]. In spite of this, there continues to be controversy about the potential protective effect of obesity in COPD. Although it has been shown that, in patients with COPD, being overweight or obese had a protective effect against mortality [@pone.0105220-Cao1], an analysis of the NHANES III cohort has reported that obesity is associated with increased mortality among participants with obstructive lung disease [@pone.0105220-Jordan1]. Furthermore, the increase in dyspnea induced by obesity could worsen the prognosis of these patients. In fact, it has been reported that persistent dyspnea and dyspnea development are risk factors for all-cause, cardiovascular and respiratory mortality in COPD patients, and that dyspnea effects on mortality are more pronounced in obese and older subjects [@pone.0105220-Figarska1].

Our results give supporting data to link obesity with the systemic inflammatory COPD phenotype. In COPD patients, the association between circulating CRP levels and BMI has previously been demonstrated [@pone.0105220-Broekhuizen1]. Is has also been shown that the presence of elevated plasma CRP concentrations is associated with increased risk for the development of cardiovascular comorbidity [@pone.0105220-Sin1]. From the PAC-COPD study, one of the three COPD subtypes included patients with milder airflow limitation and a high proportion of obesity, cardiovascular disorders, diabetes and systemic inflammation [@pone.0105220-GarciaAymerich1]. Most of the features of the so-called metabolic syndrome, including obesity, higher levels of triglycerides, diabetes, ischemic heart disease, arterial hypertension and elevated serum levels of C-reactive protein and fibrinogen, were clustered in this COPD subtype. So, obesity might be a marker for the proposed "chronic systemic inflammatory syndrome", which contributes to the comorbidities that frequently co-exist in patients with COPD [@pone.0105220-Fabbri1].

Our study, however, presents several limitations. The evaluation of the nutritional state of the patients was based on BMI and we did not have any information regarding body composition. We do not have a longitudinal follow-up of the patients; therefore, it was not possible to evaluate the relationship between obesity throughout the progression of the disease. Furthermore, our sample presents a very small number of patients with severe or very severe disease because it provides a representative sample of the population distribution seen in COPD, with a predominance of milder patients.

To conclude, our study provides evidence of the higher prevalence of obesity in a population-based sample of patients with COPD. Moreover, our results show that obesity affects the clinical manifestations, quality of life and exercise tolerance of COPD patients, and that obesity might help define a phenotype characterized by increased systemic inflammation and greater frequency of cardiovascular comorbidity.
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**Comparisons between COPD subgroups excluding patients with asthma-COPD overlap syndrome.** Combined file includes Table S1-S4. **Table S1**. General characteristics, functional status and severity of the COPD groups excluding the patients with mixed COPD-asthma phenotype. **Table S2**. Comparison of symptoms, previous exacerbations, health status and systemic biomarker levels between the study groups excluding the patients with mixed COPD-asthma phenotype. **Table S3**. Adjusted comparisons of health status, exercise tolerance and systemic inflammatory biomarkers between the study groups excluding the patients with mixed COPD-asthma phenotype. **Table S4**. Adjusted risk of comorbidity and respiratory symptoms in overweight and obese COPD patients compared with normal-weight COPD patients excluding the subjects with mixed phenotype COPD-asthma. Values are adjusted for gender, age, packs-year and FEV1 (% pred.).
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